Imagion Biosystems is pleased to report that we closed the first quarter of FY2021 maintaining a strong cash balance and having added a new study site for our Phase I HER2 Breast Cancer Study. You can read more about the status and progress of the study and other key achievements in the quarter in our latest Appendix 4C and Quarterly Activity Report.
Positive Final Results of Wayne State Collaboration Drives Completion of Phase 2 Study Protocol for IND Submission to FDA in December
December 2, 2025
Positive Final Results of Wayne State Collaboration Drives Completion of Phase 2 Study Protocol for IND Submission to FDA in December Key Highlights: MagSense® HER2